Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy
Provided By PR Newswire
Last update: Jun 23, 2025
Developed to address EGFR inhibitor-induced skin toxicities in cancer patients
NEW YORK, June 23, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they will host a virtual Key Opinion Leader (KOL) event on Tuesday, June 24, 2025, at 3:30PM EST. Access/join the event through the following link: https://zoom.us/j/91353016981.
Read more at prnewswire.com
